Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,460,624.84 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $425,640. This trade represents a 85.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Dianthus Therapeutics Trading Up 0.2%

NASDAQ DNTH opened at $108.10 on Friday. Dianthus Therapeutics, Inc. has a 12 month low of $24.49 and a 12 month high of $117.88. The stock has a market cap of $5.91 billion, a price-to-earnings ratio of -26.05 and a beta of 1.24. The company’s 50 day moving average is $105.23 and its two-hundred day moving average is $89.08.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $401,990,000. California State Teachers Retirement System increased its holdings in shares of Dianthus Therapeutics by 10,003.2% in the second quarter. California State Teachers Retirement System now owns 4,100,301 shares of the company’s stock worth $399,697,000 after purchasing an additional 4,059,717 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DNTH has been the subject of a number of analyst reports. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial lifted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wedbush upped their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $126.92.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.